Display options
Cite
Polansky H, Itzkovitz E, Javaherian A. Clinical study of Gene-Eden-VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases. Clin Transl Med. 2016;5(1):40doi: 10.1186/s40169-016-0121-6.
Polansky, H., Itzkovitz, E., & Javaherian, A. (2016). Clinical study of Gene-Eden-VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases. Clinical and translational medicine, 5(1), 40. https://doi.org/10.1186/s40169-016-0121-6
Polansky, Hanan, et al. "Clinical study of Gene-Eden-VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases." Clinical and translational medicine vol. 5,1 (2016): 40. doi: https://doi.org/10.1186/s40169-016-0121-6
Polansky H, Itzkovitz E, Javaherian A. Clinical study of Gene-Eden-VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases. Clin Transl Med. 2016 Dec;5(1):40. doi: 10.1186/s40169-016-0121-6. Epub 2016 Oct 20. PMID: 27766602; PMCID: PMC5073089.
Copy Download .nbib Format: NLM
Share it on

Clin Transl Med. 2016 Dec;5(1):40. doi: 10.1186/s40169-016-0121-6. Epub 2016 Oct 20.

Clinical study of Gene-Eden-VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases.

Clinical and translational medicine

Hanan Polansky, Edan Itzkovitz, Adrian Javaherian

Affiliations

  1. The Center for the Biology of Chronic Disease (CBCD), 616 Corporate Way, Suite 2-3665, Valley Cottage, NY, 10989, USA. [email protected].
  2. The Center for the Biology of Chronic Disease (CBCD), 616 Corporate Way, Suite 2-3665, Valley Cottage, NY, 10989, USA.

PMID: 27766602 PMCID: PMC5073089 DOI: 10.1186/s40169-016-0121-6

Abstract

BACKGROUND: We conducted a clinical study that tested the effect of suppressive treatment with the botanical product Gene-Eden-VIR/Novirin on genital herpes. Our previous paper showed that the treatment decreased the number of genital herpes outbreaks without any side effects. It also showed that the clinical effects of Gene-Eden-VIR/Novirin are mostly better than those reported in the studies that tested acyclovir, valacyclovir, and famciclovir. The current paper reports the effect of suppressive treatment with Gene-Eden-VIR/Novirin on the duration of outbreaks, in severe and mild genital herpes cases.

METHODS: The framework was a retrospective chart review. The population included 137 participants. The treatment was 1-4 capsules per day. The duration of treatment was 2-48 months. The study included three controls: baseline, no-treatment, and dose-response.

RESULTS: The treatment decreased the duration of outbreaks in 87 % of participants and decreased the mean duration of outbreaks from 8.77 days and 6.7 days in the control groups to 2.87 days in the treatment group (P < 0.001, both groups). All participants reported no adverse experiences.

CONCLUSIONS: This paper shows that suppressive treatment with Gene-Eden-VIR/Novirin decreased the duration of genital herpes outbreaks, in both severe and mild cases, without any side effects. Based on the results reported in this and our previous paper, we recommend suppressive treatment with Gene-Eden-VIR/Novirin as a natural alternative to both suppressive and episodic treatments with current drugs, in both severe and mild genital herpes cases. Trial registration ClinicalTrials.gov NCT02715752 Registered 17 March 2016 Retrospectively Registered.

Keywords: Acyclovir; Famciclovir; Genital herpes; Natural treatment; Outbreaks; Valacyclovir

References

  1. JAMA. 1984 Apr 27;251(16):2103-7 - PubMed
  2. Am J Kidney Dis. 2013 May;61(5):723-9 - PubMed
  3. J Infect Dis. 1998 Sep;178(3):603-10 - PubMed
  4. Biochemistry (Mosc). 2014 Dec;79(13):1635-52 - PubMed
  5. N Engl J Med. 2004 Jan 1;350(1):11-20 - PubMed
  6. Sex Transm Dis. 2003 Mar;30(3):226-31 - PubMed
  7. Control Clin Trials. 2004 Dec;25(6):535-52 - PubMed
  8. Front Microbiol. 2016 Mar 23;7:369 - PubMed
  9. PLoS One. 2014 Oct 15;9(10):e110216 - PubMed
  10. Scand J Infect Dis. 2005;37(8):611-613 - PubMed
  11. Br J Dermatol. 2001 Apr;144(4):818-24 - PubMed
  12. J Infect Dis. 2012 Apr 1;205(7):1100-10 - PubMed
  13. Arch Intern Med. 2008 Jun 9;168(11):1137-44 - PubMed
  14. Am J Med. 1988 Aug 29;85(2A):20-5 - PubMed
  15. Am J Kidney Dis. 1993 Oct;22(4):611-5 - PubMed
  16. Clin Microbiol Rev. 2016 Jan;29(1):149-61 - PubMed
  17. Clin Infect Dis. 2006 Jan 1;42(1):8-13 - PubMed
  18. J Clin Virol. 2014 Dec;61(4):608-10 - PubMed
  19. Drug Des Devel Ther. 2016 Aug 29;10 :2713-22 - PubMed
  20. Cochrane Database Syst Rev. 2014 Aug 03;(8):CD009036 - PubMed
  21. Front Cell Infect Microbiol. 2015 Sep 24;5:66 - PubMed
  22. Arch Intern Med. 1997 Feb 10;157(3):343-9 - PubMed
  23. J Am Acad Dermatol. 2007 Aug;57(2):238-46 - PubMed
  24. Contemp Clin Trials. 2015 Jul;43:1-9 - PubMed
  25. N Engl J Med. 2004 May 6;350(19):1970-7 - PubMed

Publication Types